Advancing Psychedelics Research and Development

Developing a pipeline of patent pending, cost effective cGMP psychedelic compounds for the furtherance of mental health and neurological disorders research.

We're creating a new approach for dealing with mental health and addiction

Core One Labs is a Canadian life sciences biotechnology company focused on research, development, and production of biologically synthesized (biosynthesized) cGMP API grade psychedelic compounds, as well as the advancement of psychedelic assisted modalities for the treatment of various mental health and neurological disorders.


The Company’s shares trade on the Canadian Securities Exchange (“CSE”) under the trading symbol “COOL,” on the OTC under the trading symbol “CLABF,” and on the Borse Frankfurt Exchange under the symbol “LD6, WKN: A3CSSU”.

Our Leadership Team

Dr. Santiago Ferro

Chief Medical Officer

Dr. Ferro is a world-renowned physician with over 20 years’ experience in pharmaceuticals, biologicals and biotech industries. Dr. Ferro has held many prestigious senior research and development positions with global responsibilities for clinical development programs, design, implementation, and analysis of clinical trials data, and has a proven record of generating and building relationships, managing projects from concept to completion, as well as designing clinical plans to meet market targets and bringing products to success.

A graduate of Javeriana University Medical School in his native Bogotá, Colombia, Dr. Ferro specialized in Internal Medicine, and later received his sub-specialty training in Infectious Diseases at the University of Toronto. Following completion of his medical and specialty training, he returned to Bogotá and established a private practice in both Internal Medicine and Infectious Diseases, while at the same time holding academic positions at different teaching hospitals.

Over the years, Dr. Ferro built a distinguished reputation in his fields of study, having over twenty-five scientific publications in peer reviewed journals and medical textbooks; and being featured in multiple international scientific conferences.

Joel Shacker

Chief Executive Officer

Mr. Shacker has worked extensively in the cannabis and finance space over the last 7 years. During his time as the CEO of Thoughtful Brands Inc, a vertically integrated ecommerce cannabis company, Mr.Shacker led the company from a non revenue generating entity, to one that generates over $30,000,000 per year. He has overseen operations across North America, Europe, Central America and South America. Mr. Shacker has been on the board of numerous public companies which have collectively raised over $50,000,000. His expertise in the emerging medical cannabis market, coupled with his business acumen to implement successful growth strategies, has allowed him to become one of the top young CEO’s in the public markets. He has acquired and integrated over 20 different assets across multiple industries, resulting in over $150,000,000 in acquisitions over his career.

Jan Burian

Chief Technical Officer at Vocan Biotechnologies

Dr. Burian is a successful biochemist and molecular biologist with extensive knowledge in operations, scale-up of fermentative API-production, research and development. He has numerous academic publications to his name. He previously held a site directorship with Pfizer.